"Lock-in"-cycloSal-pronucleotides - A new generation of chemical Trojan horses?

Mini-Reviews in Medicinal Chemistry

Volumn 4, Issue 4, 2004, Pages 383-394

  Meier, Chris ^a   Ruppel, Manuel F H ^a   Vukadinovic, Dalibor ^a   Balzarini, Jan ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXYADENOSINE; 2',3' DIDEOXY 2' FLUOROADENOSINE; 2',3' DIDEOXYADENOSINE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; ABACAVIR; ACICLOVIR; AMPHOLYTE; BENZYL DERIVATIVE; BUTYL HYDROPEROXIDE; CARBOVIR; CYCLIC NUCLEOTIDE; ESTER DERIVATIVE; FLOXURIDINE; HYDROXYL GROUP; NUCLEOSIDE ANALOG; PRODRUG; SALIGENIN; SODIUM DIHYDROGEN PHOSPHATE; STAVUDINE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CYTOSTASIS; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG POTENCY; EPSTEIN BARR VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HYDROLYSIS; LIPOPHILICITY; NONHUMAN; PROTON TRANSPORT; REVIEW; STRUCTURE ACTIVITY RELATION; TRANSESTERIFICATION; VARICELLA ZOSTER VIRUS; VIRUS INHIBITION;

EID: 3042561444     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557043403972     Document Type: Review

References (62)

1. Meier, C. Mini-Rev. Med. Chem., 2002, 2, 219;
2. Meier, C. Angew. Chem., 1996, 108, 77;
3. Meier, C. Angew. Chem. Int. Ed. Engl., 1996, 35, 70.
4. Farrow, S.N.; Jones, A.S.; Kumar, A.; Walker, R.T.; Balzarini, J.; De Clercq, E. J. Med. Chem., 1990, 33, 1400.
5. Shimizu, S.I.; Balzarini, J.; De Clercq, E.; Walker, R.T. Nucleosides & Nucleotides, 1992, 11, 583.
6. Meier, C.; Habel, L.W.; Balzarini, J.; De Clercq, E. Liebigs Annalen der Chemie, 1995, 2203.
7. Meier, C.; Muus, U.; Renze, J.; Naesens, L.; De Clercq, E.; Balzarini, J. Antiviral Chem. & Chemother., 2002, 13, 101
8. Muus, U.; De Clercq, E.; Balzarini, J.; Naesens, L.; Meier, C. Nucleosides, Nucleotides & Nucleic Acids, 2003, in press.
9. Valette, G.; Pompon, A.; Girardet, J.-L.; Cappellacci, L.; Franchetti, P.; Grifantini, M.; La Colla, P.; Loi, A.G.; Pé rigaud, C.; Gosselin, G.; Imbach, J.-L. J. Med. Chem., 1996, 39, 1981.
10. Westheimer, F.H. Acc. Chem. Res., 1968, 1, 70.
11. Buchwald, S.L. Pliura, D.H.; Knowles, J.R. J. Am. Chem. Soc., 1984, 106, 4916.
12. Meier, C.; Lorey, M.; De Clercq, E.; Balzarini, J. Bioorg. Med. Chem. Lett., 1997, 7, 99
13. Meier, C.; Lorey, M.; De Clercq, E.; Balzarini, J. J. Med. Chem., 1998, 41, 1417.
14. Ducho, C.; Balzarini, J.; Naesens, L.; De Clercq, E.; Meier, C. Antiviral Chem. & Chemother., 2002, 13, 129
15. Meier, C.; Renze, J.; Ducho, C.; Balzarini, J. Current Topics in Med. Chem., 2002, 2, 1111.
16. Müller, C.; Meier, C. 2003, unpublished results.
17. Naesens, L.; Meier, C. 1998, unpublished results.
18. Balzarini, J. 2000, unpublished results. It should be added that salicyl alcohol (saligenin) is used as part of the antirheumatic and analgetic drug Salicin (2-[hydroxymethyl]phenyl-β-D-glucopyranoside; Assalix®). β-Glucosidase hydrolyzes Salicin to D-glucose and saligenin and the latter is then slowly oxidized by cytochrome P450 to salicylic acid in the blood and in the liver:
19. Chen, G.; Fournier, R.L.; Varanasi, S. Enzyme Microb. Technol., 1997, 21, 491;
20. Steinegger, E.; Hoevel, H.. Pharm. Acta Helv., 1972, 47, 222
21. Ducho, C.; Balzarini, J.; Meier, C. Nucleosides, Nucleotides & Nucleic Acids, 2003, 22, 841.
22. Ducho, C.; Meier, C.; Balzarini, J. J. Med. Chem., 2004, in press.
23. Balzarini, J.; Aquaro, S.; Knispel, T.; Rampazzo, C.; Bianchi, V.; Perno, C.-F.; De Clercq, E.; Meier, C. Mol. Pharmacol., 2000, 58, 928.
24. Gröschel, B.; Meier, C.; Zehner, R.; Cinatl, J.; Doerr, H.W.; Cinatl Jr., J. Nucleosides & Nucleotides, 1999, 18, 933.
25. Meier, C.; Knispel, T.; De Clercq, E.; Balzarini, J. Bioorg. Med. Chem. Lett., 1997, 7, 1577.
26. Meier, C.; Knispel, T.; De Clercq, E.; Balzarini, J. J. Med. Chem., 1999, 42, 1604.
27. Knispel, T.; Meier, C. Nucleosides & Nucleotides, 1999, 18, 945.
28. Johnson, M.A.; Fridland, A. Mol. Pharmacol., 1989, 36, 291.
29. Ahluwalia, G.; Cooney, D.A.; Mitsuya, H.; Fridland, A.; Flora, K.P.; Hao, Z.; Dalal, M.; Broder, S.; Johns, D.G. Biochem. Pharmacol., 1987, 36, 3797.
30. Gao, W.-Y.; Agbaria, R.; Driscoll, J.S.; Mitsuya, H. J. Biol. Chem., 1994, 269, 12633.
31. Meier, C.; Knispel, T.; Marquez, V.E., De Clercq, E.; Balzarini, J. Nucleosides & Nucleotides, 1999, 18, 907;
32. Meier, C.; Knispel, T.; Marquez, V.E.; Siddiqui, M.A.; De Clercq, E.; Balzarini, J. J. Med. Chem., 1999, 42, 1615.
33. Different names for the nucleoside analogues 17 and 18 could be found. Terms as F-up- and F-down-ddA, F-ara- and F-ribo-ddA, as well as 2′,3′-dideoxy-2′-fluoroarabinosyladenine and 2′,3′-dideoxy-2′-fluororibosyladenine have been used. Here we use the abbreviation F-β- and F-α-ddA. The correct names are 9-(2′,3′-dideoxy-2′-fluoro-β -D-threo-pentofuranosyl)adenine (17) and 9-(2′,3′ -dideoxy-2′-fluoro-β-D-erythro-pentofuranosyl)adenine (18)
34. Marquez, V.E.; Tseng, C.K.-H.; Mitsuya, H.; Aoki, S.; Kelley, J.A.; Ford, Jr., H.; Roth, J.S.; Broder, S.; Johns, D.G.; Driscoll, J.S. J. Med. Chem., 1990, 33, 978.
35. Herdewijn, P., Pauwels, R., Baba, M., Balzarini, J.; De Clercq, E. J. Med. Chem., 1987, 30, 2132.
36. Mu, L.; Sarafianos, G.; Nicklaus, M.C.; Russ, P.; Siddiqui, M.A.; Ford, Jr.; H.; Mitsuya, H.; Le, R.; Kodama, E.; Meier, C.; Knispel, T.; Anderson, L.; Barchi, Jr., J.J.; Marquez, V.E. Biochemistry, 2000, 39, 11205.
37. Ford, H., Jr.; Dai, F.; Mu, L.; Siddiqui, M.A.; Nicklaus, M.C.; Anderson, L.; Marquez, V.E.; Barchi, J.J., Jr. Biochemistry, 2000, 39, 2581.
38. Meier, C.; De Clercq, E.; Balzarini, J. Nucleosides & Nucleotides, 1997, 16, 793.
39. Meier, C.; De Clercq, E.; Balzarini, J. Eur. J. Org. Chem., 1998, 837.
40. Lorey, M.; Meier, C.; De Clercq, E.; Balzarini, J. Nucleosides & Nucleotides, 1997, 16, 789;
41. Lorey, M.; Meier, C.; De Clercq, E.; Balzarini, J. Nucleosides & Nucleotides, 1997, 16, 1307.
42. Balzarini, J.; Naesens, L.; Aquaro, S.; Knispel, T.; Perno, C.-F.; De Clercq, E.; Meier, C. Mol. Pharmacol., 1999, 56, 1354.
43. Balzarini, J.; Haller-Meier, F.; De Clercq, E.; Meier, C. Antiviral Chem. & Chemother., 2002, 12, 301.
44. De Clercq, E. Biochemical Pharmacol., 1984, 33, 2159.
45. Fields, B.N. Virology, (Vol. 1) 2nd edition, Raven Press, New York, 1990, 450.
46. Wutzler, P. Intervirology, 1997, 40, 343.
47. Meier, C., Habel, L.; Haller-Meier, F.; Lomp, A.; Herderich, M.; Klöcking, R.; Meerbach, A.; Wutzler, P. Antiviral Chem. Chemother., 1998, 9, 389.
48. Meerbach, A.; Klöcking, R.; Meier, C.; Lomp, A.; Helbig, B.; Wutzler, P. Antiviral Research, 2000, 45, 69.
49. De Clercq, E.; Meier, C. 1998, unpublished results.
50. De Clercq, E.; Descamps, J.; De Somer, P.; Barr, P. J.; Jones, A.S.; Walker, R.T. Proc. Natl. Acad. Sci. USA, 1979, 76, 2947.
51. De Clercq, E. Clinical Microbiol. Rev., 1997, 10, 674.
52. Anagnostopoulos, I.; Hummel, M. Histo-Pathol., 1996, 29, 297.
53. Meier, C.; Lomp, A.; Meerbach, A.; Wutzler, P. ChemBioChem, 2001, 2, 283.
54. Meier, C.; Lomp, A.; Meerbach, A.; Wutzler, P. J. Med. Chem., 2002, 45, 5157;
55. Meier, C.; Lomp, A.; Meerbach, A.; Wutzler, P. Nucleosides, Nucleotides & Nucleic Acids, 2001, 20, 4.
56. Nagata, W.; Okada, K.; Aoki, T. Synthesis, 1979, 365.
57. Brechbühler, H; Büchi, H.; Hatz, E.; Schreiber, J.; Eschenmoser, A. Helv. Chim. Acta, 1965, 48, 1746.
58. Garber, S.B.; Kingsbury, J.S.; Gray, B.L.; Hoveyda, A.H. J. Am. Chem. Soc., 2000, 122, 8168.
59. Breton, G.W. J. Org. Chem., 1997, 62, 8952.
60. Yamada, S.; Sugaki, T.; Matsuzaki, K. J. Org. Chem., 1996, 61, 5932.
61. Van Boom, J.H.; Burgers, P.M.J. Tetrahedron Lett., 1976, 52, 4875.
62. Saboulard, D.; Naesens, L.; Cahard, D.; Salgado, A.; Pathirana, R.; Velazquez, S.; McGuigan, C.; De Clercq, E.; Balzarini, J. Mol. Pharmacol., 1999, 56, 693.